Molecular Partners AG (SWX:MOLN)
Switzerland
· Delayed Price · Currency is CHF 2.870
-0.040 (-1.37%)
Aug 15, 2025, 5:30 PM CET
Molecular Partners AG Revenue
Molecular Partners AG had revenue of 2.23M CHF in the twelve months ending March 31, 2025, down -66.82% year-over-year. In the year 2024, Molecular Partners AG had annual revenue of 4.97M, down -29.38%.
Revenue (ttm)
2.23M
Revenue Growth
-66.82%
P/S Ratio
42.91
Revenue / Employee
14.04K
Employees
159
Market Cap
95.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.97M | -2.07M | -29.38% |
| Dec 31, 2023 | 7.04M | -182.56M | -96.29% |
| Dec 31, 2022 | 189.60M | 179.85M | 1,843.82% |
| Dec 31, 2021 | 9.75M | 410.00K | 4.39% |
| Dec 31, 2020 | 9.34M | -11.04M | -54.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.49B |
| Novartis AG | 43.89B |
| Lonza Group AG | 7.09B |
| Alcon | 8.77B |
| Galderma Group AG | 3.73B |
| Sandoz Group AG | 8.42B |
| Straumann Holding AG | 2.58B |
| Sonova Holding AG | 3.87B |
Molecular Partners AG News
- 7 weeks ago - Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 - GlobeNewsWire
- 2 months ago - Molecular Partners to cut jobs, cash reach now anticipated to extend into 2028 - Seeking Alpha
- 2 months ago - Molecular Partners to cut workforce by a quarter - Reuters
- 2 months ago - Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway - GlobeNewsWire
- 3 months ago - Molecular Partners to Present at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Molecular Partners reports Q1 results - Seeking Alpha
- 3 months ago - Molecular Partners: Sluggish Progress But Worth Monitoring (Rating Downgrade) - Seeking Alpha
- 4 months ago - Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025 - GlobeNewsWire